Why China’s vaccines are gaining international momentum

There has been much news of late concerning coronavirus disease 2019 (Covid-19) vaccine progress from the two big American pharmacy firms, Pzifer and Moderna. It is hardly a surprise that the mainstream media behave as if these are the only two vaccine options available in the world and give them preferential coverage. However, equal to the progress these companies have made, a number of Chinese firms are also pacing forward with third stage clinical trials of a coronavirus vaccine.

These include SinoVac, CanSino and SinoPharm. Although they have not publicized their results to market their products in the way the two US companies have, nevertheless it has been reported that trials of these vaccines have yielded positive results, had no adverse effects and owing to different methodologies, do not require being frozen at extreme temperatures in order to facilitate distribution.